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ABSTRACT
Two collections of oligonucleotides have been
designed for preparing pangenomic human and
mouse microarrays. A total of 148993 and 121703
oligonucleotides were designed against human and
mouse transcripts. Quality scores were created in
order to select 25342 human and 24109 mouse
oligonucleotides. They correspond to: (i) a BLAST-
specificity score; (ii) the number of expressed
sequence tags matching each probe; (iii) the dis-
tance to the 30 end of the target mRNA. Scores were
also used to compare in silico the two microarrays
with commercial microarrays. The sets described
here, called RNG/MRC collections, appear at least as
specific and sensitive as those from the commercial
platforms. The RNG/MRC collections have now been
used by an Anglo-French consortium to distribute
more than 3500 microarrays to the academic com-
munity. Ad hoc identification of tissue-specific
transcripts and a  80% correlation with hybridiza-
tions performed on Affymetrix GeneChip suggest
that the RNG/MRC microarrays perform well.
This work provides a comprehensive open resource
for investigators working on human and mouse
transcriptomes, as well as a generic method to
generate new microarray collections in other organ-
isms. All information related to these probes, as
well as additional information about commercial
microarrays have been stored in a freely-accessible
database called MEDIANTE.
INTRODUCTION
Microarray technologies for expression proﬁling may be split
into two broad categories, platforms that are based on in situ
synthesis of oligonucleotide probes and those that are based
of the deposition of preassembled DNA probes. The ﬁrst
class of array platforms is dominated by the commercial
sector with a number of companies, e.g. Affymetrix (1),
Nimblegen (2), Agilent (3), offering a range of off-the-shelf
or custom arrays to their customers. Microarrays fabricated
using preassembled probes have traditionally been favoured
by many academic laboratories and are also available from
a number of commercial sources e.g. GE Healthcare’s Code-
link platform (4), Illumina’s ‘BeadChip’ arrays (5). Primarily
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tories still favour the use of spotted arrays made in-house
for their research.
For a number of years the fabrication of spotted micro-
arrays largely relied on the attachment of gene fragments
ampliﬁed from cDNA libraries (6). Whilst this approach
clearly works and can provide useable tools for expression
analysis, it suffers from several fundamental limitations:
gene representation within cDNA libraries is incomplete;
there is often a signiﬁcant degree of redundancy within
clone collections; annotation of clones can be ﬂawed and
cDNA libraries often come with legal restrictions on their
distribution and use. Furthermore, the relatively large size
of the cDNA amplicons can be associated with the presence
of repeat sequences or homology to related genes, which can
compromise the speciﬁcity of the probes in an unpredictable
way (7). An alternative approach that addresses this issue
involves the production of gene-speciﬁc DNA fragments by
PCR ampliﬁcation using speciﬁc primers (8–10). Existence
of a signiﬁcant fraction of genes where a speciﬁc PCR amp-
licon cannot be designed or generated, as well as the high
costs and technical difﬁculty of DNA production, makes
this approach impractical for the fabrication of mammalian
whole genome expression microarrays.
An alternative approach for probe synthesis for spotted
microarray production has come through the use of long
(50–70mers) oligonucleotides (11,12). A signiﬁcant reduction
in the cost of production of the synthetic oligonucleotides, an
improvement of the quality control provided by the different
suppliers and the ability to design one or several speciﬁc
probes to any given target sequence, has made the use of
long oligonucleotides for the fabrication of microarrays a
very attractive option. As a result, the last few years have
seen a number of companies offering aliquots of oligonuc-
leotide libraries for array fabrication. Transcript coverage
has then increasing alongside our knowledge of transcript
diversity. However, these sets have been relatively expensive
to purchase and the small aliquots provided can severely limit
the utility of the resource. In addition, though less of an issue
now, the design criteria and the sequence of the oligonuc-
leotides often remained proprietary. Finally, the use of a
diverse range of probe sets by different laboratories has
made comparison of data between groups difﬁcult (13–19).
In order to address the need for improved access and
standardization of microarray resources within the academic
biomedical research community, a programme to develop
long-oligonucleotide resources for every human and mouse
gene was created. Speciﬁcally, a collaboration was launched
between the French Genopole Network (RNG), a consortium
of French laboratories involved in functional genomics, and
the Microarray Programme of the MRC Rosalind Franklin
Centre for Genomics Research, which had a remit to provide
spotted microarrays for human and mouse expression analysis
to the UK academic community. The primary objective of the
project was to develop an open-access probe resource that
would support the fabrication of high quality cost effective
microarrays in UK and French academic laboratories. To
ensure that probe design was open, dynamic and that annota-
tion of the resources was kept up to date and available to
the wider community, the creation of ad hoc bioinformatics
tools was also central to the project.
Here we describe the bioinformatic pipeline that has been
used in the design of two pangenomic oligonucleotide collec-
tions for study the expression proﬁling of human and mouse
systems. This includes in silico validation steps and bench-
mark comparisons with commercial human and mouse
oligonucleotide probe collections, and the creation of an
open-access database called MEDIANTE, which integrates
information about the RNG/MRC, Affymetrix, Agilent and
Illumina probe sets. Lastly, we present experimental valida-
tion data obtained after hybridizing distinct RNAs originating
from human or mouse tissues on microarrays spotted with the
RNG/MRC probe collections.
MATERIALS AND METHODS
Oligonucleotide design
Transcript selection. Two non-redundant sets of mRNA
sequences (one for human and one for mouse) were assembled
from RefSeq, a database derived from GenBank. These were
subjected to BLAST sequence analysis (20) against UniGene.
Out of the 105680 representative sequences from human
UniGene clusters (build #167), 87386 did not match this
ﬁrst RefSeq selection (build #33 for human). When UniGene
clusters corresponding to less than 4 sequences were
excluded, there were 2979 UniGene clusters of more than 4
sequences associated with at least 1 RNA sequence, which
did not match any RefSeq transcript. The representative
RNA from each of these UniGene clusters was then intro-
duced into the list of transcripts selected for oligo design.
Sequences deﬁned in Affymetrix and Agilent human micro-
array annotations were then compared to this second list
in order to identify sequences which were not represented.
Following this selection the ﬁnal number of human tran-
scripts selected for oligo design was 29894. BLAT analyses
(21) ensured that each sequence was correctly positioned on
to the genome sequence. Similar analysis were performed
for the mouse, based on RefSeq (build #32) and the 86213
Unigene clusters (build #125) and resulted in the selection
of 25002 mouse transcripts.
Calculation of oligonucleotide probes. After transcript selec-
tion, OligoArray2.0 (22,23) was used to calculate probes.
This software integrates BLAST analysis against a non-
redundant set of sequences and probe secondary structure
analyses (24). Oligonucleotide calculation parameters were
set as follows: oligo length from 50 to 52mers; GC percent-
age from 40 to 60%; maximum distance to 30 end of transcript
less than 1500 bases; melting temperature from 84 to
94 C. OligoArray 2.0 selected probes with the lowest cross-
hybridization, the absence of secondary structure and bal-
anced the set of probes in terms of melting temperature.
After the OligoArray2.0 calculation, all oligonucleotides
matching with splice variants were grouped by transcript.
Oligonucleotides containing ﬁve consecutive A, C, G or T’s
were discarded.
Sub-selection of an oligonucleotide library for synthesis.
Following the calculation of all potential probes, there were
approximately ﬁve oligos designed against each transcript.
An automatic procedure was then set up to select the
‘optimal’ probe from these. To this end, three distinct criteria
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number of EST’s matching the probe and (iii) the position
of the probe from the 30 end of the target transcript.
1. Speciﬁcity. Whilst a speciﬁcity analysis is integral to
OligoArray, it was necessary to set up an additional speciﬁ-
city check outside the program in order to re-evaluate the
design of the probe sets when new releases of Ensembl or
RefSeq became available. To this end, each oligonucleotide
was compared to three distinct BLAST formatted databases:
the ﬁrst database was composed of the 29894 human tran-
scripts selected for this study (or 25002 mouse transcripts),
the second database corresponded to the current release of
RefSeq protein-encoding transcripts, and the third to the
current Ensembl collections of transcripts. Evaluation of the
speciﬁcity of each oligo probe against these three databases
was adopted in order to minimize biases caused by the pro-
cess of transcript selection. A perfect-match between a
50mer and the corresponding transcript is associated with a
BLAST expect-value of  10
 20. However, any 50mer can
perfectly match more than one transcript, for instance when
the probe sequence is shared by several splice variants, or
when it matches distinct members of a same gene family.
Furthermore, a 50mer can also match imperfectly other trans-
cripts. In this case, the number of hits is not constant, but
increases along with the BLAST expect-value. We set up a
decimal score, called X_HYBRID, where the integer part
depicts the Blast-speciﬁcity of the probe, and the decimal
part depicts the number of Blast hits. In that context, the
most speciﬁc probe available for a transcript will correspond
to the one associated with the lowest X_HYBRID
value. This deﬁnition is explained in detail in Figure 1,
which shows the number of hits obtained for a 50mer at dif-
ferent levels of the BLAST expect-values. According to the
deﬁnition of the X_HYBRID, oligonucleotides with no
cross-hybridization at a BLAST expect-value equal to 1
have a X_HYBRID equal to 0. The higher the X_HYBRID
score, the lower the speciﬁcity of the oligonucleotide.
Table 1 shows the relationship existing between X_HYBRID
scores and the number of matching nucleotides. Typically,
oligonucleotides with X_HYBRID equal to 1,x (where x
is any integer from 1 to 9) can match 16 consecutive
bases with a homologous sequence, or 19 bases out of
20 (Table 1). Experimental data support the fact that such
probes are still speciﬁc (data not shown). Oligos with a
X_HYBRID value superior to 2.0 can perfectly match with
sequences of more than 18 bases, but can also match
21 bases out of 22, or 27 bases out of 30. Most probes with
X_HYBRID > 2 were removed from the ﬁnal selection. In the
rare cases where they were selected, this was only when no
better probes were available for the corresponding transcript.
2. Comparison with expressed sequence tags. mRNA
species derived from a single loci can vary in exon usage
(splice variants) or the length of the 30 end due to the use
Table 1. Relationship existing between the X_HYBRID scores and the
number of matching nucleotides in Blast hits
Number of Mismatchs 0 1 2 3 4
X_HYBRID ¼ 0 14/14 17/18 20/22 23/26 26/30
X_HYBRID ¼ 1.x 16/16 19/20 22/24 25/28 28/32
X_HYBRID ¼ 2.x 18/18 21/22 24/26 27/30 30/34
X_HYBRID ¼ 3.x 20/20 22/23 25/27 28/31 31/35
X_HYBRID ¼ 4.x 21/21 24/25 27/29 30/33 33/37
X_HYBRID ¼ 5.x 23/23 26/27 29/31 31/34 35/39
X_HYBRID ¼ 6.x 41/41 44/45 47/49 — —
For instance, a probe with a X_HYBRID score equal to 2.1 can match its
BLAST hit by 18 identical bases out of 18 (no mismatch), or 21 out of 22
(one mismatch) or 24 out of 26 (two mismatches).
Figure 1. Definition of the X_HYBRID specificity score. Typical picture of a probe specificity analysis, as available from the MEDIANTE interface (http://
www.microarray.fr). Each column represents the number of BLAST hits in the MEDIANTE database (blue), Ensembl database (green), RefSeq database (red)
for the BLAST expect-value indicated at bottom. The X_HYBRID score for a probe was calculated as the maximal x_hybrid scores among the three databases.
Based on expect-values equal to 10, 1, 10
 1,1 0
 2,1 0
 3,1 0
 4,1 0
 15,1 0
 20, a ‘rank’ was defined, ranging from 0 for an expect-value equal to 10 to 6 for
an expect-value equal to 10
 15. For instance, the oligonucleotide depicted in Figure 1 has an extra hit in RefSeq for an expect-value of 10
 1, thus defining a rank
equal to 2. The number of extra hits between the rank and the lowest expect-value is called delta (D). In the example shown in Figure 1, D is equal to 1. D is
always kept in the interval from 1 to 9, meaning that when there are more than 9 extra hits, D is kept to 9. A x_hybrid score is defined for each BLAST database
(i.e. MEDIANTE, RefSeq, Ensembl) as a decimal number, where the integer part corresponds to the rank, and the leftovers to D. The final X_HYBRID score for
a probe is defined as the maximal x_hybrid score obtained against the 3 BLAST databases.
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oligonucleotides that hybridized to the most invariant part
of each transcript we counted the number of EST hits
for each probe, as probes designed against alternatively
spliced exons or 50 end sequences are likely to hit fewer
30 EST’s. We used the LASSAP (26) implementation of
BLAST to compare all oligos probes against dbEST data-
bases (27). The number of EST’s matching (95% identity)
each oligonucleotide in the database (called EST_NUMBER)
NUMBER) was counted. Additional information, such as the
tissue of origin of the EST was also recorded. All information
was stored in the MEDIANTE database. LASSAP has been
optimized for such an intensive task, where 270700 oligos
had to be compared against 7057754 human and 4688047
mouse EST’s.
3. ‘Optimal’ probe selection and synthesis. After having
deﬁned the X_HYBRID, EST_NUMBER and DIST_TO_30
scores (the latter corresponding to the distance to the 30 end
of the transcript) for every couple of probe and transcript,
selection of the ‘optimal’ human and mouse sets was per-
formed using these three criteria. In order to select highly
speciﬁc probes, the ﬁrst criterion selected for each transcript
the probes exhibiting the lowest X_HYBRID scores. The
second criterion selected into this subset the probe(s) with
the highest EST_NUMBER values. Probes from the ﬁrst
subset having an EST_NUMBER superior or equal to 60%
of this maximal value were rescued and stored in a second
subset (this cut-off is explained in Supplementary Figure 1).
For each transcript, the optimal probe was deﬁned as the
most 30 probe belonging to the second subset. After this
ﬁrst selection, which favours the selection of Blast-speciﬁc
oligonucleotides, we checked whether probes characterized
by an intermediate X_HYBRID score (X_HYBRID < 2)
and by an EST_NUMBER score at least ﬁve times superior
to the EST_NUMBER score of the selected probe, were
available. This step allowed the selection of probes with min-
imal cross-hybridizations, but matching a much larger num-
ber of ESTs. Such situations may happen due to alternative
splicing, leading to the existence of two transcripts with dif-
ferent levels of expression. Among such probes, the most
30 sequence was selected.
For several transcripts, we selected several additional
oligonucleotides to analyse the variations of the ratios and/
or intensities between probes targeting a same transcript.
Based on these criteria a subset of 25342 human and
24109 mouse oligonucleotides were selected for synthesis.
A total of 100 mmoles of each probe were ordered from
Sigma–Proligo (Paris, FRANCE) as a 50 amino modiﬁed
oligonucleotide. Oligonucleotide stocks were aliquoted and
distributed to participating laboratories for use in microarray
fabrication.
Comparison of the probes sets with commercial
probe sets
In order to compare our oligonucleotide selection with other
probe collections, we performed an in silico comparison
between the human and mouse RNG/MRC probe sets with
probes present on Affymetrix (human U133Plus2 and mouse
MG-U74), Agilent (HumanGenome and MouseGenome), and
Illumina (Illumina_human and Oligator_MEEBO_mouse)
microarrays. The analysis of the Affymetrix GeneChips
probes was restricted to the ﬁrst and last perfect-match probes
of each probe set. Three comparisons were carried out, for
each of the three scores: X_HYBRID, EST_NUMBER, and
DIST_TO_30. These comparisons took place within a subset
of probes of 16303 human and 13073 mouse transcripts rep-
resented on all four microarray platforms. For each of the
three commercial platforms the same approach was taken to
calculate X_HYBRID, EST_NUMBER and DIST_TO_30
scores for each probe.
However, a direct comparison of BLAST scores was not
possible, due to the different lengths of the probes
(25 bases for Affymetrix, 50 for RNG/MRC, 60 for Agilent
and 70 for Illumina). Several analyses were therefore perfor-
med, where sub-sequences were randomly selected within
RNG/MRC, Agilent and Illumina probes in order to generate
BLAST queries of uniform length. Libraries of 25mers
derived from RNG/MRC, Agilent and Illumina collections
were constructed, as well as libraries of 50mers derived
from Agilent and Illumina collections. In order to reduce
the bias caused by the selection of ‘random’ 25mers, the
procedure was independently repeated three times for each
set, and these scores were only used for global descriptive
statistics. The three independent measurements indeed led
to the same results, therefore demonstrating that shortening
the length of the probes had no impact on the results of our
analyses.
Mediante web application
The development of the project has required the creation of a
dedicated database, aimed at storing all oligonucleotide
sequences. This database has been called MEDIANTE.
MEDIANTE is a J2EE platform deployed under a Tomcat
web server. It is based on a PostgreSQL relational database.
This database contains annotations pertaining to transcripts
and oligonucleotides in 45 distinct tables. Thirty additional
tables are used to store the information about hybridizations
(K. Le Brigand and P. Barbry, manuscript in preparation).
The human and mouse RNG/MRC probe collections and
all associated information can be directly downloaded from
the MEDIANTE home page (http://www.microarray.fr).
Subscription is managed by the French National Genopole 
Network, and provides access to some additional tools, such
as customized selection of oligonucleotides, or storage of
microarray data.
Probe update and evaluation. The current MEDIANTE data-
base has now gone through six different iterations as updated
versions of Ensembl, RefSeq and Unigene have been released
(Supplementary Figure 2). Upon each new RefSeq release, an
automatic process is launched in order to update the ‘optimal’
RNG/MRC oligonucleotide collections. This process inte-
grates: (i) an update of transcripts with an altered sequence,
(ii) the identiﬁcation of transcripts absent from the current
set, (iii) the design of new oligonucleotides and the construc-
tion of ad hoc relationships between all oligonucleotides
and all transcripts, (iv) an update of the oligonucleotides
‘optimal’ selection. The aim of this automatic process is for
each transcript to check whether the oligonucleotide currently
selected is always the ‘optimal’ probe available. The whole
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nucleotides that were selected in a previous version of the
collections, with no need to re-calculate whole collections
with OligoArray.
Annotation of the probe sets. Transcript annotations were
derived from several public databases. All information is
currently accessible and can also be freely downloaded within
the framework of MEDIANTE. A search tool allows the user
to browse according to GenBank accession numbers,
LocusLink ID, Unigene ID, gene symbol, within sequence
descriptors, exact Gene Ontology terms (28,29), chromo-
somal localization. Each query is built dynamically after
collection of the information and is returned via a web
form. The list of relevant transcripts is identiﬁed, and then
visualized. An important feature is the publication of
information about several commercial platforms (Affymetrix,
Agilent and Illumina). BLAST analyses have been used to
position all probes in the RNG/MRC and commercial sets
on each transcript included in MEDIANTE. This makes it
possible to compare probes belonging to any of these four
distinct platforms (see Figure 5). This information appears
particularly useful to highlight differences existing between
probes from different platforms, especially when conﬂicting
data are collected from different platforms or probes.
Personal project manager. One of the initial remits of
MEDIANTE was to provide the possibility for a distant
user to participate to the improvement of the oligonucleotide
collection. A typical scenario corresponds to the selection of
a subset of probes for speciﬁc transcripts, for instance to
allow the design of bespoke microarrays. The user can
either upload FASTA-formatted (30) sequences or query in
MEDIANTE sequences of interest. When all sequences
have been collected, the user can compare their sequences
with all the oligonucleotides. This BLAST analysis allows
the determination of oligonucleotides that match with the
query sequences. A pre-selection of the ‘optimal’ probe is
performed according to the method explained above, but
the user can still change these parameters according to their
preferred criteria. The selection of probes is very similar to
a ‘shopping basket’, where the user collects progressively
the list of probes needed for their project. At the end of
the selection process, all information about the selected
oligonucleotides and their associated annotation (transcript
information, chromosomal localization, probe sequence,
etc.) can be either downloaded, or stored in the database for
subsequent analysis. This virtual microarray can also be
transferred to another collaborator registered to MEDIANTE,
so that several users can cross-check the selection of probes.
This method has been very useful during the development of
the RNG/MRC collection, and has then been used for crea-
ting a custom-made human microarray, which is currently
used by several laboratories. Information about this micro-
array is also available on the entry page of MEDIANTE.
Experimental evaluation
Array preparation. Oligonucleotides were diluted to a ﬁnal
concentration of 35–50 mM in 35% dimethyl sulfoxide
(DMSO), 100 mM potassium phosphate (pH 8.0). Pange-
nomic microarrays were printed using human RNG/MRC
oligonucleotide collection with a ChipWriterProarrayer
(Bio-Rad, 1000 Alfred Nobel Drive Hercules, CA) on
commercial HydroGel slides (Schott, Hattenbergstr
1055122 Mainz, Germany), and processed according to the
manufacturer’s instructions.
RNA labelling and hybridization. RNAs were labelled using
an ampliﬁcation protocol, as described in Moreilhon et al.
(9). Brieﬂy, 1 mg of total RNA was ampliﬁed with the Amino
Allyl MessageAmp aRNA kit (Ambion, 2130 Woodward
Austin TX) according to manufacturer’s instructions. Cy3
and Cy5 labelled aRNA was fragmented with the Ambion
aRNA Fragmentation Reagents, puriﬁed and made up in
Agilent hybridization buffer. Labelled cRNAs were then
hybridized to RNG/MRC human pangenomic microarrays
in an oven at 62 C for 16 h. Microarrays were washed
and scanned with a Genepix scanner (Axon Instruments,
Molecular Devices Corporation 3280 Whipple Road Union
City, CA). Hybridization of Affymetrix GeneChip  was per-
formed according to standard protocols, as suggested by the
supplier.
Microarray analysis. TIF images containing the data
from each ﬂuorescence channel were quantiﬁed with the
Genepix pro 5.0 program (Axon Instruments). Data were
log-transformed, mean-centered and reduced for an equal
standard deviation between each slide (Z-score), using the
GeneANOVA software (31). Normalization was performed
using the limma package available in Bioconductor (http://
www.bioconductor.org). Tissue-speciﬁc probes were deﬁned
as probes with a Z-score superior to 100 times the average
Z-scores in the other three conditions. Clustering was per-
formed using Bioconductor (32,33) and TM4 (34). GeneChip
One-Cycle Target Labeling (Affymetrix) and the recommen-
ded protocols from the Affymetrix Eukaryotic Sample
Analysis Technical Manual, revision 5 (Affymetrix SOP)
were used for the experiment shown on Figure 6.
RESULTS
Oligonucleotide design process
Statistics on RNG/MRC and several commercial probe col-
lections are summarized in Table 2. The X_HYBRID score
deﬁnes the speciﬁcity of the set. A total of 68.9% (17457
probes) and 23.4% (5921) of the 25342 RNG/MRC human
probes have a X_HYBRID score equal to zero, or below 2,
respectively. A total of 7.7% (1964 probes) have a
X_HYBRID score above 2 indicating a possible cross-
hybridization with other transcripts (as assessed by Blast ana-
lyses). They were nevertheless selected as no better probe
could be identiﬁed. A very similar picture was obtained for
the RNG/MRC mouse probes (24109 probes) with 69.6%
(16767) probes with a X_HYBRID equal to zero, 23.1%
(5563) probes with a X_HYBRID below 2, and 7.4% (1779)
probes with a X_HYBRID above 2. Comparison of the
probes with EST databases (dbESTs), demonstrated that the
25342 oligonucleotides of the ﬁnal human selection matched
1282376 distinct EST’s (>95% identity). The 24109 mouse
probes collection matched 926311 distinct EST’s. On aver-
age, 53 EST’s were hit by each human and 39 for each
mouse probe.
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base has now gone through six successive versions, as
updates of Ensembl and RefSeq have been released. The
fourth version of the human probes selection was used for
the design of the synthetized human oligonucleotide collec-
tion, the so called RNG/MRC human probe set. Similarly,
the second version of the mouse probes selection corresponds
to the version used for the synthesis of the mouse collection,
the so called RNG/MRC mouse probe set. Supplementary
Figure 2 indicates the evolution of the probes collection
during several successive versions of the databases.
Comparison of the probes sets with commercial
probe sets
Comparison of the RNG/MRC probe sets with commercial
platforms i.e. Affymetrix, Agilent and Illumina was per-
formed on 16303 human transcripts represented in all four
collections of human probes and on 13073 mouse transcripts
represented in all four collections of mouse probes.
Figure 2 summarizes the comparison of the X_HYBRID
scores between probes from RNG/MRC, Affymetrix, Agilent
and Illumina platforms. As explained in the ‘Materials and
Methods’ section, a direct comparison of the four platforms
Table 2. Descriptive statistics for RNG/MRC, Affymetrix, Agilent and Illumina probe collections
Human Mouse
Probes Transcripts Probes Transcripts
Number of distinct RNG/MRC sequences 148 993 29 894 121 703 26 058
Number of distinct gene symbols — 21 043 — 22 740
Total number of RNG/MRC probes 25 342 29 894 24 109 25 002
Number of RNG/MRC probes with x_hyb ¼ 0 17 457 — 16 767 —
Number of RNG/MRC probes with x_hyb ¼ 1,x 5921 — 5563 —
Number of RNG/MRC probes with x_hyb > 1,y 1964 — 1779 —
Average EST_NUMBER per RNG/MRC probe 53 — 39 —
Average DIST_TO_30score per RNG/MRC probe 692 — 488 —
Affymetrix U133Plus2 / MG-U74 108 371
a 27 588
b 89 502
a 20 624
b
Agilent whole genome 40 990 25 627
b 20 865 18 087
b
Illumina human / MEEBO 22 548 21 271
b 36 362 22 463
b
Oligonucleotides with X_HYBRID equal to 0 or to 1,x are considered ‘BLAST-specific’ probes; oligonucleotides with a X_HYBRID equal to x,y (x > 1) can
possibly cross-hybridize with other transcripts. They were selected only when no better probe was available for a given transcript. For Affymetrix, comparison was
performed for the first and last 25mer probes of each perfect-match Affymetrix probe sets (a probe set is specific to a gene and is composed of an average of ten
25mer probes).A total of 90% of the transcripts have a majorityof their associatedoligonucleotides characterizedby a X_HYBRIDscorebelow 2. Less than 5%of
the transcripts are only associated with oligonucleotides characterized by a X_HYBRID score above 2.
aOnly the first and last probes from each Affymetrix probe set were used for analysis.
bNumber of transcripts matched by probes from the RNG/MRC transcript selection set.
Figure 2. Blast-specificities of the different probe collections. (A) Average X_HYBRID scores for the different human and mouse collections. (B) Percentage of
probes in each set associated with a X_HYBRID above 2, i.e. less ‘BLAST-specific’. This comparison has been performed on a subset of 16,303 human and
13,073 mouse transcripts, common to all platforms. ALL represents the collection of all probes calculated with OligoArray2.0. RNG/MRC represents the
selection of probes used for the fabrication of the microarrays.
e87 Nucleic Acids Research, 2006, Vol. 34, No. 12 PAGE 6 OF 13was not possible due to the different probe sizes used by the
different platforms: from 25 bases (Affymetrix), 50 bases
(RNG/MRC), 60 bases (Agilent) to 70 bases (Illumina). To
circumvent this problem, three independent calculations
were made with three randomly shortened probes, in order
to work with BLAST queries of the same length between
the different collections. Figure 2 values represent averages
of the three resulting values. Figure 2B shows the percentage
of probes with a X_HYBRID superior to 2 as a function of
the length of the BLAST query, according to the source of
the oligonucleotide. A total of 10–15% of the 148993
human and of the 121703 mouse oligonucleotides selected
with OligoArray (entitled ALL in Figures 2–3) have a
X_HYBRID score above 2. A similar percentage is observed
for the oligonucleotides from Agilent and Illumina. This per-
centage decreases below 5% for the probes derived from the
RNG/MRC or Affymetrix collections. A similar trend is
observed in Figure 2A for the average X_HYBRID score of
each set. Based on this in silico analysis the RNG/MRC probe
resources would appear to be more speciﬁc than the two
commercial long-oligonucleotide probe collections.
Figure 3 summarizes the comparison of the EST_
NUMBER scores among platforms. Figure 3B shows the
percentage of probes in each set that do not match any
ESTs. More than 12% of the 148993 human and of the
121703 mouse oligonucleotides selected with OligoArray
(ALL) do not recognize any EST. A large difference can be
noticed between the 50 and 30 oligonucleotides from Affymet-
rix. In that case, the difference in EST_NUMBER can clearly
be explained by their relative distance to the 30 end of the
transcript (see also Figure 4). Figure 3A indicates the average
EST_NUMBER score per set. As for the X_HYBRID score,
we randomly shortened RNG/MRC, Agilent and Illumina
probes to 25 bases, so that their size did not differ with the
size of Affymetrix probes. This sampling was performed
three times, and gave identical results (data not shown).
While the average EST_NUMBER led to similar scores for
all platforms, the RNG/MRC probes mapped to a slightly
larger number of EST’s in both human and mouse than the
other platforms.
The position of the probe with regard to the 30 end of the
transcript, represented by the DIST_TO_30 score, was then
analysed. The distribution of the distance for the RNG/
MRC probes and the three other sets is shown on Figure 4.
As might be expected the Affymetrix probe sets show distinct
peaks associated with the 50 and 30 oligonucleotides. Agilent,
Illumina and the RNG/MRC probe collections display a
similar pattern of distribution with the majority of probes
being located within the 600 last base pairs of the 30 region.
of the target mRNA.
Experimental evaluation of the RNG/MRC
oligonucleotides collection
Expression profiling of human cell types versus ‘electronic
northern’. A ﬁrst experimental evaluation of our selection of
oligonucleotides was provided by a comparison of experi-
mental data and in silico data (Supplementary Figure 3).
For this purpose, we compared the results obtained after
hybridization of 45 RNG/MRC microarrays with diverse
human RNA originating from leucocytes (7 microarrays),
nasal epithelial cells (22 microarrays), keratinocytes
(4 microarrays) and liver (12 microarrays), in order to identi-
fy a set of tissue-speciﬁc transcripts, characterized by a strong
Figure 3. Matches with human and mouse EST databases for the different probe collections. (A) Average EST_NUMBER scores for the different human and
mouse collections. (B) Percentage of probes matching no ESTs for All MEDIANTE probes, for the RNG/MRC, Agilent, Illumina and Affymetrix probe sets. For
human, the comparison was performed on a subset of 7,325 transcripts having ‘BLAST-specific’ probes in all sets, i.e. X_HYBRID lower than 2.0. For mouse,
the comparison was performed on a subset of 6,358 such transcripts. A matching EST was defined by a 95% identity between one probe and an EST.
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the three others. A total of 481 oligonucleotides were selected
by their high EST_NUMBER scores in at least one of the
four studied tissues, and by a differential expression between
the four tissues, as assessed by the results of the hybridiza-
tions on the RNG/MRC microarrays. Hierarchical clustering
of these 481 probes revealed several tissue-speciﬁc clusters.
Supplementary Figure 3 (left panel) shows a heat map of
these 481 genes. A black signal is associated with a high
level of expression, as measured by the intensity of the
ﬂuorescence. Annotations of the EST’s (see Materials and
Methods) was used to count the number of EST’s from
immune cells (Immune), respiratory tissues (Respiratory),
skin (Skin) or liver (Liver) matching these 481 probes.
Supplementary Figure 3 (right panel) shows a heat map
derived from this analysis. Despite the fact that the samples
analysed here are from similar but ultimately different bio-
logical sources, several similarities can be noticed between
the two plots. This suggests some relationship between the
intensity of the signal and the number of expressed
transcripts.
Comparison of hybridizations on RNG/MRC microarrays
versus hybridizations on Affymetrix GeneChip . In order to
directly evaluate expression proﬁles generated with the
RNG/MRC microarrays, RNA derived from either HEK293
cells or a human cell line of keratinocytes (DK7) was
analysed in parallel on the RNG/MRC platform, or on an
Affymetrix platform. Figure 6 shows the relationship existing
between ratios established with Affymetrix arrays (x-axis)
and ratios established with RNG/MRC arrays (y-axis).
When considering only the genes for which the average
intensity of the signal was superior to the 25th percentile
for both platforms, the coefﬁcient of correlation between
Figure 4. Distribution of the probes according to their DIST_TO_30 score.
(A) human. (B) mouse. More than 90% of probes for the human sets and 98%
of probes for the mouse sets are located within 1,500 bases from the 30-end of
target mRNAs. Legend indicates the average DIST_TO_30 score for each
collection. This comparison has been performed on a subset of 16,303 human
and 13,073 mouse transcripts, common to all sets.
Figure 5. MEDIANTE screenshot of the summary data for transcript NM_001652. The different exons of each transcript are represented by dark and light blue
boxes. The RNG/MRC probes are represented on the first line; the light green box indicates the ‘current optimal probe’. The red box indicates the RNG/MRC
probe(s). The blue box indicates a probe selected for a local microarray production. Each set of probes is represented on a distinct line. Affymetrix probe sets are
represented by their first and last 25-mer perfect match probes. Additional information about the transcript or probes, such as gene chromosomal location, probe
specificity, etc. are provided as clickable links. Subforms provide information about Gene Ontology annotations, bibliographic references or tissue-specificity.
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0.700 when all data points are considered, and raised to
0.880 when considering the genes for which the average
intensity of the signal was superior to the 75th percentile
for both platforms.
Independent validation of the probes. More than 3500 RNG/
MRC microarrays have been already distributed to more than
100 distinct projects. A total of 4666 probes, targeting 4522
distinct transcripts, have been so far conﬁrmed by independ-
ent measurements. More precisely, a probe was validated
when a ratio above 2 was detected in an experiment using
a RNG/MRC microarray and when an independent measure-
ment (quantitative RT–PCR, other microarray platforms,
northern blots, protein detection or functional assays) led
to a similar variation (i.e. ratio above 2 for RNA detection,
or increased protein expression, or increased activity). Such
probes are listed in Supplementary Table 1. Validated probes
are also ﬂagged in the Mediante interface.
Validation of the EST_NUMBER and DIST_TO_30 scores.
For several transcripts, we selected distinct oligonucleotides
to analyse the variations of the ratios and/or intensities
between probes targeting a same transcript. In the experiment
shown on Figure 6, 75% of such pairs of RNG/MRC probes
were correlated (meaning that log2ratio[probe1] ¼ log2ra-
tio[probe2] ± 1). This suggests that our selection was indeed
able to select probes with similar properties. We then anticip-
ated that the 25% of the probes exhibiting divergent proper-
ties might shed some light on the relative importance of
EST_NUMBER, distance to 30 ends, or Tm (the latter being
the most commonly accepted parameter for the selection of
probes). In an independent mouse microarray experiment,
we selected 34 such pairs of probes, characterized by at
least a 2-fold variation in intensity. We wondered whether
a positive difference in intensity could be attributed to: (i) a
positive difference in EST_NUMBER, (ii) a negative differ-
ence in the DIST_TO_30 and/or (iii) a positive difference in
melting temperature of the probes. Figure 7 summarizes in
a Venn diagram our results: 100% of such pairs of probes
were correlated with either a variation in EST_NUMBER
(24 transcripts), DIST_TO_30 (30 transcripts) and/or Tm
(14 transcripts). All information, as well as additional
information about sequences, enthalpies, entropies of the
probes are available in Supplementary Table 2.
DISCUSSION
The last 5 years have seen a signiﬁcant increase in the
accessibility and diversiﬁcation of microarray platforms for
performing expression analyses (35–39). In particular, the
range of species for which commercial arrays are now avail-
able and the number of probe features per microarray have
expanded dramatically due to improved sequence resources
and technological advances in microarray fabrication. As a
result, applications of microarray analysis to many ﬁelds of
basic and biomedical research have dramatically increased
(40–42). However, the cost of commercial arrays is still
prohibitive for many large academic projects.
To address the problem of accessing affordable arrays,
a number of academic communities have established
centralized facilities for microarray fabrication (43). Much
of the early work of these centers relied on the use of
cDNA clone sets for generating probe resources for microar-
ray fabrication. Incomplete gene coverage, inaccurate gene
annotation, contaminated or missing clones, legal restrictions
which were often associated with the use of cDNA libraries,
made these resources non-optimal for microarray production.
Furthermore, and perhaps most importantly, the large size of
the DNA probe used for any given gene has a potential to
cross-hybridize to other sequences, due to partial homology
to other genes or presence of repeat sequences. The accep-
tance and availability of oligonucleotide probe resources
for spotted microarray fabrication has provided a powerful
alternative to the use of cDNAs (44–53). The ﬁrst aim of
our project was to provide an open probe resource for the
fabrication of cost effective pangenomic microarrays to
Figure 7. Analysis of 34 mouse transcripts targeted by 2 distinct RNG/MRC
probes. Shown are probes with a variation in intensity greater than 2 fold.
Each number corresponds to the number of transcripts for which fluorescence
intensity varied along with EST_NUMBER, DIST_TO_30 and/or Tm.
Figure 6. Scatter plot of the ratios measured on Affymetrix GeneChip 
(x-axis) and on RNG/MRC microarrays (y-axis). RNA was derived from
either HEK293 cells or a keratinocyte cell line (DK7). 11053 transcripts had
at least one Affymetrix probe set and one RNG/MRC probe. Among them,
7054 pairs were further analyzed, as their intensity level was larger than the
25
th percentile on both platforms. After quantification of the signals on both
platforms, the ratio of the expression levels between the two cell lines was
established. The coefficient of correlation was equal to 0.81.
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addressed more general issues:
(i) The development of an open-access repository for human
and mouse probes usable in gene expression studies
provides a useful tool to compare the position of the
probes from several sources. Knowledge and comparison
of these probes is crucial in assessing probe specificity
and in performing cross-platform comparisons. While
this part of our project has some similarities with
the Resourcerer (54) and Dragon projects (55), the
MEDIANTE web interface provides graphical represen-
tations of all probes associated with a specific transcript
(Figure 5). Although limited at the moment to RNG/
MRC, Agilent, Illumina and Affymetrix probe collec-
tions in human and mouse, this visualization tool will be
extended in the near future to include other platforms
and other organisms.
(ii) Whilst access to the RNG/MRC probe libraries and
arrays fabricated from them may be restricted to the
French and UK communities, the MEDIANTE interface
provides an open-access portal to a detailed description
of the probe sets. It also allows any end-users to select a
preferred set of probes, according to some specific
knowledge. With currently a selection of probes 148993
human and 121703 mouse transcripts precalculated in
the database, MEDIANTE can easily be used to define
probes against specific splice variants or subsets of
genes. Thus the tool can be viewed as both a gene
annotation tool and as a convenient tool to create
dedicated microarrays.
(iii) The storage of hybridization data in a centralized
data warehouse, integrated within MEDIANTE, will
allow the integration of both probe and experimental
information. Validation tools will allow fast quality
control of the data and easy generation of a MIAME-
compliant export format (56). As such, it will facilitate
the transmission by end-users of their curated data to
public repositories, such as GEO (57) or ArrayExpress
(58), based on the MAGE-ML language (59). In
addition, the ongoing production of human and mouse
pangenomic microarrays using the RNG/MRC probe
sets by groups funded by either the French ‘Re ´seau
National Genopoles’ (RNG, French Genopole Network)
or the UK Medical Research Council means that
many are now essentially using the same probe
resources for their work. This will clearly facilitate the
construction of homogeneous large datasets available
for Meta-analysis.
The quality scores used in the current study provide a con-
venient way to evaluate probe design and compare between
different sets of probes. Following on from the initial design
of the ‘full’ set of probes generated by the OligoArray pro-
gram, our probe selection procedure allowed for further
reﬁnement of the probe collection.
The X_HYBRID score represents a simpliﬁed output of
BLAST analyses and its use integrates BLAST analyses per-
formed on three distinct databases (MEDIANTE, RefSeq,
Ensembl). This index has several interesting characteristics.
First, it varies along with the BLAST score (the lower the
X_HYBRID score is, the more ‘BLAST-speciﬁc’ a probe is).
Secondly, visualization through MEDIANTE, according to
the representation shown in Figure 1, integrates results from
our three references databases, giving indications about vari-
ations of the annotations among databases.
A 2-fold enrichment in the number of ‘zero’ probes
(i.e. probes having a X_HYBRID score equal to 0) was
observed between the ‘ALL’ collection of probes generated
by OligoArray and the selection of the optimal probe sets.
In the same way, a 4-fold decrease in the number of probes
having a X_HYBRID score greater than 2 was observed
between the ‘ALL’ collection of probes generated by
OligoArray and the selection of the optimal probe sets (see
Figure 2B). This enrichment was similar in human and in
mouse (data not shown). The presence of ‘low-speciﬁcity’
probes in the full collections of probes may appear surprising,
since OligoArray supposedly rejects non-speciﬁc probe
sequences. However, the presence of these probes may be
due to: (i) an absence of high quality probes available for a
given sequence, since OligoArray provides its ‘best’ available
candidates, even though none may be entirely speciﬁc, (ii)
the presence of new transcripts in more recent releases of
RefSeq or Ensembl, which increases the X_HYBRID score
of the probe, or (iii) the correction of previous versions of
mRNA sequence due to sequencing error. In our hands, the
X_HYBRID score allows a dynamic re-evaluation of a set
of probes every time a new release of sequences is available.
This makes possible the use of a collection of probes over
numerous iterations (Supplementary Figure 2). This approach
differs from the approach developed with programs such
as OligoArray, where a re-calculation of new probes can
lead to considerable disparity with older versions of a design.
From that perspective, we consider that our approach simpli-
ﬁes the cycle of life of a probe collection. The X_HYBRID
score was particularly helpful for comparing sets from several
distinct microarray platforms. In human as well as in mouse,
the RNG/MRC and Affymetrix probe sets were always
associated with lower X_HYBRID scores than Agilent or
Illumina probe sets.
The second criterion used to select probes corresponded to
the EST_NUMBER. It was initially set up in order to avoid
the selection of probes speciﬁc to rare or poorly expressed
splice variants. As a direct count of the number of EST’s
associated with each probe, this index provided an easy meas-
ure of the relative sensitivity of each probe to detect its target.
Comparison of the EST_NUMBER scores of RNG/MRC sets
with commercial collections was also favourable to the RNG/
MRC collections, in terms of the average number of EST
identiﬁed per probe, and in terms of the number of probes
matching no EST’s (see Figure 3). With the availability of
additional information about the tissue of origin of each, it
was possible to divide the EST_NUMBER into 26 categories
according to the libraries from which the EST’s were
sequenced (Brain, Eye, Heart, Muscle, Pancreas, Liver, Stom-
ach, GI tract, Kidney, Bladder, Testis, Prostate, Respiratory,
Otorhinolaryngology, Skin, Immune, Bone, Breast, Uterus,
Ovary, Placenta, Stem cell, Embryo, Fibroblast, Adipose tis-
sue and Cancer). The relative number of EST’s in each cate-
gory therefore provided an estimate of the abundance of the
transcripts in the corresponding tissue, category or cell type.
These values were used to draw Supplementary Figure 3.
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be linked to some extent to DIST_TO_30. Our selec-
tion strategy indeed took into account the few cases where
EST_NUMBER scores are not directly related to
DIST_TO_30.
The fact that 75% pairs of RNG/MRC probes targeting a
same transcript (Figure 6) share similar levels of expression
is a good indication of the quality of our design. Besides,
the analysis of the 25% remaining pairs of probes showed
that differences can be correlated with differences in
DIST_TO_30, EST_NUMBER or Tm. This argue in favour
of the use of these parameters.
We noticed a convergence over time of the design of an
optimal collection of oligonucleotide probe (Supplementary
Figure 2). This probably corresponds to the overall reduction
in the number of new/novel sequences for each organism over
time. This point is suggested by the fact that no signiﬁcant
changes were made to our process over the period of re-
evaluations. We anticipate that further iterations will provide
marginal improvements to the optimal probe sets already
available for studying human and mouse transcriptomes.
The in silico validation studies presented here (Figures 2-4) of
the RNG/MRC probe collections suggests that they compare
well with three commercial platforms. However, more
extensive experimental analyses of these observations will
be required to conﬁrm this.
A ﬁrst experimental validation of RNG/MRC microarrays
focused on the identiﬁcation of clusters of genes speciﬁc to at
least one of four distinct tissues or cell types (leucocytes,
nasal epithelium cells, keratinocytes or liver) (Supplementary
Figure 3). Several tissue-speciﬁc transcripts were identiﬁed
after hybridization, which correspond to classical markers
of these tissues: this was the case of HLA molecules in
immune cells, of keratins in keratinocytes, or of albumin in
liver. The similar patterns revealed by heatmaps representing
hybridization data or EST_NUMBER scores (Supplementary
Figure 3) support the idea that we correctly identiﬁed tissue-
speciﬁc traits. These observations suggest good overall
agreement between experimental results provided by hybrid-
ization of the RNG/MRC arrays and the annotation of the
probes. Several additional validations have been provided
elsewhere for speciﬁc sets of probes that were identiﬁed
after using the RNG/MRC microarrays (9,60,61). Additional
results are summarized in Supplementary Table 1, where
validated probes are indicated.
A second, and to our opinion, more deﬁnitive demon-
stration of the quality of the collections was provided after
comparing two distinct RNAs on the RNG/MRC human
microarray and on the Affymetrix GeneChip . The high
coefﬁcient of correlation (>0.8) observed between the two
distinct comparisons represents a deﬁnitive demonstration
of the quality of our design. More elaborate experimental
design, such as those described in Barnes et al. (5) or in de
Reynies et al. (62) may in the future help deﬁning more
precisely sets of probes providing highly reproducible
results.
Whilst it is difﬁcult to anticipate the future of the micro-
array ﬁeld (especially the role that will be played by aca-
demic facilities in array fabrication), genome-wide analysis
of the human and mouse transcriptomes is now almost a
routine procedure in an increasing number of laboratories.
The need for comprehensive microarrays covering all known
human and mouse genes, composed of homogeneous sets of
probes has never been greater. As the technology arrives at
this point in maturity, the development of additional proper-
ties, for instance in order to discriminate splice variants, will
require new efforts. The current work is a contribution to this
quest, and represents, to our knowledge, the ﬁrst report integ-
rating probe design, microarray fabrication and experimental
validation.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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